A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

This study will use a study design known as a REMAP, a Randomised, Embedded, Multifactorial, Adaptive Platform trial. The broad objective of this REMAP is, over time, to determine and continuously update the optimal set of treatments for community-acquired pneumonia.